BVSNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Bioventus Inc.
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Aug 5, 2026
$13.49+0.19 (+1.43%)
Close on Oct 19, 2026
- Market cap
- $955.61M
- P/E (TTM)
- 17.5
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Gross margin
68.3%−4.4 pts over 5 years
Operating margin
9.5%+2.9 pts over 5 years
Net margin
4.0%−1.1 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -0.9% | +3.5% | +12.1% | – | |
| Gross profit | -0.0% | +5.4% | +10.7% | – | |
| Operating income | – | – | +20.5% | – | |
| Net income | – | – | +6.7% | – | |
| Free cash flow | +90.8% | – | +5.5% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 13.7% | |
| Return on assets | – | – | 3.2% | |
| Current ratio | – | 1.73 | 1.70 | |
| Debt to equity | – | – | 1.60 | |
| Net debt to EBITDA | – | 2.04× | 2.40× | |
| Inventory turnover | – | – | 2.1× | |
| Capex to revenue | – | 5.2% | 0.5% | |
| Diluted shares | – | – | 69M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Bioventus generated $165.34M from operations and spent $25.93M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$165.34M
Used
$25.93M
Capital expenditure$25.93M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin4.0%
×Asset turnover0.80×
×Equity multiplier4.25×
=Return on equity, FY202513.7%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | 4.0% | 0.80× | 4.25× | 13.7% |
| FY2024 | -6.3% | 0.75× | 4.79× | -22.5% |
| FY2023 | -30.5% | 0.47× | 4.38× | -62.6% |
| FY2022 | -31.0% | 0.39× | 3.31× | -40.5% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
8of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero$22.73M
- Cash generatingOperating cash flow above zero$74.67M
- Return on assets improvedROA up on the prior year-4.5% → 3.1%
- Earnings backed by cashOperating cash flow above net income$74.67M vs $22.73M
- Less leverageLong-term debt to assets fell42.3% → 40.8%
- Better liquidityCurrent ratio rose1.31 → 1.70
- No dilutionShare count did not rise65M → 69M
- Gross margin improvedGross margin up on the prior year67.72% → 68.33%
- More efficientAsset turnover rose0.71 → 0.78